Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables - Other: 2018-2025

  • China SXT Pharmaceuticals' Receivables - Other fell 72.24% to $119.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $119.1 billion, marking a year-over-year decrease of 72.24%. This contributed to the annual value of $108,281 for FY2025, which is 29.47% up from last year.
  • According to the latest figures from Q3 2025, China SXT Pharmaceuticals' Receivables - Other is $119.1 billion, which was up 109,973,025.48% from $108,281 recorded in Q1 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Receivables - Other peaked at $428.9 billion during Q3 2024, and registered a low of $83,634 during Q1 2024.
  • Over the past 3 years, China SXT Pharmaceuticals' median Receivables - Other value was $59.5 billion (recorded in 2023), while the average stood at $162.4 billion.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Receivables - Other spiked by 15,509,667.90% in 2023 and then crashed by 72.24% in 2025.
  • Quarterly analysis of 5 years shows China SXT Pharmaceuticals' Receivables - Other stood at $3.0 million in 2021, then fell by 7.72% to $2.7 million in 2022, then soared by 15,509,667.90% to $426.3 billion in 2023, then increased by 0.62% to $428.9 billion in 2024, then crashed by 72.24% to $119.1 billion in 2025.
  • Its Receivables - Other was $119.1 billion in Q3 2025, compared to $108,281 in Q1 2025 and $428.9 billion in Q3 2024.